Nicholas Piramal to develop Morvus technologies
Nicholas Piramal (NPIL) has signed two licence agreements with the UK-based drug discovery company Morvus Technology.
By TNN |
MUMBAI: Nicholas Piramal (NPIL) has signed two licence agreements with the UK-based drug discovery company Morvus Technology. Under these agreements, the company gets the rights to develop and commercialise two of Morvus’ technologies.
The first agreement relates to Morvus’ platform technology that allows the identification of novel genes and proteins associated with programmed cell death, opening the way for therapeutic programmes to attenuate their effects.
Nicholas Piramal will be responsible for developing the technology to generate new drugs in the areas of diabetes and rheumatoid arthritis. The second agreement encompasses a combination therapy for cancer, which utilises specific Cyclin Dependent Kinase inhibitor to enhance the effectiveness of known anti-cancer drugs.
Morvus will be entitled to initial fee payments for both contracts and will also be entitled to milestone and 2% royalty payments, as potential products progress to the market.
“We are pleased to partner Morvus Technology in drug discovery platforms, which reinforce our discovery research efforts. Morvus is doing excellent work from its laboratories in the UK, a region where we continue to find excellent opportunities for partnering in high-end work,” NPIL chairman Ajay Piramal said. Since early ’05, NPIL has made significant investments in the UK across its businesses. It bought the Inhalation Anaesthetics business of Rhodia Organique Fine, UK, in January ’05 followed by acquisition of the Custom Manufacturing business of Avecia Group, UK in December ’05 and the Morpeth-based pharmaceutical manufacturing Unit of Pfizer, UK in June, ’06. With these investments, the company now has four manufacturing facilities in the UK, employing around 650 people.
The first agreement relates to Morvus’ platform technology that allows the identification of novel genes and proteins associated with programmed cell death, opening the way for therapeutic programmes to attenuate their effects.
Nicholas Piramal will be responsible for developing the technology to generate new drugs in the areas of diabetes and rheumatoid arthritis. The second agreement encompasses a combination therapy for cancer, which utilises specific Cyclin Dependent Kinase inhibitor to enhance the effectiveness of known anti-cancer drugs.
Morvus will be entitled to initial fee payments for both contracts and will also be entitled to milestone and 2% royalty payments, as potential products progress to the market.
“We are pleased to partner Morvus Technology in drug discovery platforms, which reinforce our discovery research efforts. Morvus is doing excellent work from its laboratories in the UK, a region where we continue to find excellent opportunities for partnering in high-end work,” NPIL chairman Ajay Piramal said. Since early ’05, NPIL has made significant investments in the UK across its businesses. It bought the Inhalation Anaesthetics business of Rhodia Organique Fine, UK, in January ’05 followed by acquisition of the Custom Manufacturing business of Avecia Group, UK in December ’05 and the Morpeth-based pharmaceutical manufacturing Unit of Pfizer, UK in June, ’06. With these investments, the company now has four manufacturing facilities in the UK, employing around 650 people.
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
